Nuvectis Pharma, Inc.
NASDAQ:NVCTBiotechnology
+$0.39 today
- Market cap
- $697.75M
- Beta
- -0.07
- P/E (TTM)
- -11.2
- EPS (TTM)
- -$1.16
Volume 0.19M
Average 0.08M
NVCT Total Current Liabilities
All obligations due within one year.
Nuvectis Pharma, Inc.NASDAQ: NVCT
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 21.6% from a year ago
Total current liabilities stood at $11.18M at the end of Q1 FY2026, up 21.6% from a year earlier and down 15.9% from the prior quarter. Over 3 fiscal years it compounded at +29.1% a year.
Context
- Total current liabilities amounted to 44.0% of total assets at the end of Q1 FY2026, up 13.5 pp from a year earlier.
- Total current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +21.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 13.3M USD
- Year-over-year change
- +49.5%
- 4-year CAGR
- +53.1%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.3M | +49.5% |
| FY2024 | 2024-12-31 | 8.89M | +27.3% |
| FY2023 | 2023-12-31 | 6.98M | +12.9% |
| FY2022 | 2022-12-31 | 6.19M | +155.7% |
| FY2021 | 2021-12-31 | 2.42M | — |
Total Current Liabilities vs competitors
How NVCT compares with its peers on the latest reported figures
- NVCT's Mar 2026 total current liabilities of $11.18M is the 8th highest of the 11 companies compared; the peer median is $62.88M.
- Its year-over-year change of +21.6% is the 6th highest of 11, against a peer median of +22.0%.
- Total current liabilities amounts to 44.0% of total assets for NVCT, versus a peer median of 11.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $4.97B | +97278.1% | +7.7% | 2.3% | |
| Mar 2026 | $95.94M | +73.0% | -3.9% | 44.0% | |
| Jun 2026 | $86.76M | +30.7% | +84.2% | 11.7% | |
| Mar 2026 | $86.17M | -8.9% | +60.5% | 18.2% | |
| Mar 2026 | $66.85M | +87.7% | +49.4% | 29.3% | |
| Mar 2026 | $58.92M | +236.6% | +14.8% | 5.7% | |
| Mar 2026 | $17.77M | +0.9% | +9.9% | 4.1% | |
| Mar 2026 | $11.18M | +21.6% | +29.1% | 44.0% | |
| Mar 2026 | $10.54M | +13.2% | +99.5% | 11.0% | |
| Mar 2026 | $10.28M | -31.0% | -4.8% | 5.0% | |
| Mar 2026 | $6.18M | -17.6% | -43.9% | 15.2% | |
| Peer median (excluding NVCT) | $62.88M | +22.0% | +12.4% | 11.3% | |
Competitors are the stored peer set for NVCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Nuvectis Pharma, Inc.
NASDAQ:NVCT
Intrinsic Alpha fair value
Locked
Current Price
$20.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.